Fieldfisher publishes white paper - The future of medicine: Cell and gene therapy
Leading European law firm Fieldfisher launches white paper titled 'The future of medicine: Cell and gene therapy', an insight into the regulatory landscape for cell and gene therapy in the UK and other key hotspots in Europe.
Cliodhna McDonough, life sciences lawyer, Fieldfisher comments:
"Cell and gene therapy is showing that it has the potential to revolutionise healthcare, shifting the possibilities of medicine from illness management to curative.
"While the Covid-19 pandemic did have a negative impact on funding, research, manufacturing and supply chains, we're likely to see that the new found reality for cell and gene therapy will be much more positive. In fact, the pandemic may have straightened the roads for cell and gene therapy to reach patients.
"The commitment of regulators and the flurry of attention from the media and investors on the pharmaceutical industry as they raced to find a vaccine, shows that the world's interest in the innovation that the life sciences industry can bring has been heightened.
"Cell and gene therapy is the pinnacle of innovation and now is the prime time for cell and gene therapy across Europe as the route to market becomes clearer."